Rebif®

DRUG8 trials

Conditions

Clinically Isolated SyndromeMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingRelapsing-RemittingRelapsing-remitting Multiple Sclerosis

Phase 1

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis

NCT02364986

PD Dr. Marcus MüllerRelapsing-remitting Multiple Sclerosis

Start: 2015-01-31End: 2017-01-31Target: 50Updated: 2016-06-03

Phase 3

A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome

CompletedNCT00287079

Merck KGaA, Darmstadt, GermanyClinically Isolated Syndrome

Start: 2005-10-31End: 2008-11-30Updated: 2013-12-27

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

CompletedNCT00292266

EMD SeronoMultiple Sclerosis, Relapsing-Remitting

Start: 1999-11-30End: 2002-06-30Updated: 2013-08-05

Phase 4

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

CompletedNCT00078338

EMD SeronoRelapsing-remitting Multiple Sclerosis

Start: 2004-02-16End: 2006-11-28Updated: 2018-06-27

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

CompletedNCT01791244

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis, Relapsing-Remitting

Start: 2013-02-28End: 2016-02-29Updated: 2017-08-24

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

CompletedNCT02064816

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis, Relapsing-Remitting

Start: 2014-05-31End: 2016-04-30Updated: 2018-09-20

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

TerminatedNCT02117050

EMD SeronoMultiple Sclerosis

Start: 2014-06-30End: 2015-04-30Updated: 2017-01-23

Unknown Phase

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

CompletedNCT01207648

EMD SeronoMultiple Sclerosis

Start: 2010-07-31End: 2011-07-31Updated: 2015-05-15

Related Papers

RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif

PLoS ONE2019-07-0512 citations

Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies

BMC Pharmacology and Toxicology2015-09-228 citations

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

2008-09-11327 citations